Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Atossa Genetics Inc. (NASDAQ: ATOS) shares dropped 20.31 percent to close at $2.55 a share Friday. The stock traded between $2.40 and $2.70 on volume of 4.50 million shares traded. The company announced the pricing of a public offering of roughly 5.8 million units at a price of $2.40 per unit. Shares of Atossa Genetics have fallen approximately 40.0 percent in the past year.
Get more information on Atossa Genetics and free access to the in-depth equity report at:
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares soared 50.56 percent to close at $9.41 a share Friday. The stock traded between $8.18 and $9.49 on volume 14.99 million shares traded. The company and its partner Endo Health Solutions reported positive top-line results from its pivotal Phase 3 efficacy study of BEMA buprenorphine, a treatment for chronic pain. Shares of BioDelivery Sciences have gained approximately 110.0 percent in the past year.
Get more information on BioDelivery Sciences free access to the in-depth equity report at:
PTC Therapeutics, Inc. (NASDAQ: PTCT) shares gained 2.59 percent to close at $26.90 a share Friday. The stock traded between $21.75 and $27.67 on volume 1.08 million shares traded. The company that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a negative opinion on its marketing authorization application for its muscular dystrophy treatment. Shares of PTC Therapeutics have gained approximately 60.0 percent in the past year.
Get more information on PTC Therapeutics and free access to the in-depth equity report at:
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares declined 4.39 percent to close at $15.68 a share Friday. The stock traded between $15.31 and $16.75 on volume 1.60 million shares traded. The company has priced an underwritten public offering of 2,898,550 shares of its common stock at $15.00 per share. Shares of Tonix Pharmaceuticals have gained approximately 50.0 percent year-to-date.
Get more information on Tonix Pharmaceuticals and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities